Table 2.
FDA-approved PI3K inhibitors.
Therapeutic Drug | Target (s) | Clinical Trial Status | Developer |
---|---|---|---|
Idelalisib (CAL101) | PI3Kδ inhibitor | FDA Approved | Gilead Sciences |
Copanlisib | Pan-class I PI3K inhibitor | FDA Approved | Aliqopa; Bayer |
Duvelisib (ABBV-954, INK-1197, IPI-145) | PI3Kδ/PI3Kγ inhibitor | FDA Approved | Copiktra; Verastem |